EGFR and non-small cell lung carcinoma: The most effective approach in NSCLC therapy is targeting the EGFR signaling using TK inhibitors (TKI) (Bartholomew et al., 2017; Shah and Lester, 2020; Zhang et al., 2024; Zhou et al., 2009).